Johnson & Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the European Society of Minimally Invasive Neurological Therapy (ESMINT) 9th Annual Meeting (7–9 September, Nice, France).
Cerenovus, a name derived from the Latin words for “new” and “brain”, will focus on delivering innovative therapies for haemorrhagic and ischaemic stroke patients.
Stroke is a growing health concern; in Europe, the number of strokes annually is projected to rise from 1.1 million in 2000 to 1.5 million by 2025. Meanwhile, the American Heart Association estimates someone dies of a stroke every four minutes. The annual economic cost of stroke is estimated to be €27 billion across Europe, which includes direct costs such as healthcare services and medications, and indirect costs such as lost productivity.
“We believe stroke should not be a life sentence,” said Gabriele Fischetto, vice president of Johnson & Johnson Cardiovascular Specialty Solutions in EMEA. “Cerenovus is inspired by our long heritage and dedication to improving patient lives. We believe there is no other healthcare company better positioned than us to assist in addressing the real pain points for doctors who treat stroke—from helping them work more efficiently; to achieving a higher success rate across all neurovascular cases.”
According to a company release, the Johnson & Johnson Medical Devices Companies are committed to neurovascular care, having expanded the Cerenovus product portfolio in the last year with targeted investments. The recent acquisitions of Pulsar Vascular, with a specialty in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi, offering extensive expertise and knowledge in acute ischaemic stroke with its EmboTrap Revascularization Platform, greatly extend Cerenovus’s abilities to address unmet clinical needs in these areas.
Johnson & Johnson’s neurovascular business was formerly under the name Codman Neuro.